BHVN:NYE-Biohaven Pharmaceutical Holding Co Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 51

Change

0.00 (0.00)%

Market Cap

USD 4.82B

Volume

0.71M

Analyst Target

USD 83.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 555.27B
RCUS Arcus Biosciences Inc

N/A

USD 1.51B
NUVB Nuvation Bio Inc

N/A

USD 0.80B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.45B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
ADCT ADC Therapeutics SA

N/A

USD 0.30B
CYBN Cybin Inc

N/A

USD 0.19B
ANVS Annovis Bio Inc

N/A

USD 0.11B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.09B
PLX Protalix Biotherapeutics Inc

N/A

USD 0.08B

ETFs Containing BHVN

IBRN iShares Trust - iShares N.. 5.36 % 0.00 %

N/A

USD 3.84M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.16% 44% F 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.16% 44% F 77% C+
Trailing 12 Months  
Capital Gain 96.08% 55% F 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 96.08% 55% F 92% A
Trailing 5 Years  
Capital Gain 23.16% 67% D+ 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.16% 67% D+ 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 44.25% N/A N/A 94% A
Dividend Return 44.25% N/A N/A 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 94.29% N/A N/A 8% B-
Risk Adjusted Return 46.93% N/A N/A 63% D
Market Capitalization 4.82B 96% N/A 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.